« Previous | Next » | All Messages |  CYGX Message Board Home | recommend post |  Ignore Poster

CYGX News CytoGenix Controller Appointed Interim Chief Financial Officer

HOUSTON--(BUSINESS WIRE)--CytoGenix, Inc. (OTCBB:CYGX) announces that Pamela Schertz has been appointed as interim Chief Financial Officer. Ms. Schertz has served the Company as Controller since 2003. Ms. Schertz received her BBA in Accounting from the University of Houston and is a licensed CPA in the State of Texas. After establishing her own practice offering consultant services as a CPA in October 2003, CytoGenix became her first client. Prior to working for CytoGenix, Ms. Schertz has over 15 years of experience in accounting in various industries, including a casket manufacturer, an independent power company, and an architecture firm. Management positions have included serving as Controller at a high-end clothier and at a civil engineering firm.

Malcolm Skolnick, CytoGenix Chief Executive Officer states, “As Controller, Ms. Schertz has done an outstanding job in managing the Company’s financial records, preparing the Company’s quarterly reports, and facilitating compliance with the Sarbanes-Oxley regulations. We are fortunate to have someone with her experience and ability to maintain continuity in this critical area of the Company’s operations.”

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.